Aortyx
VerifiedAortyx has developed a biomimetic bioresorbable adhesive patch to treat aortic dissections. It helps to stop false lumen blood flow, promotes natural repair and bio integration. Learn more
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$11—16m (Dealroom.co estimates Apr 2021.)
Company register number B67306423
Teià Catalonia (HQ)
- hard tech
- horizon europe
- woman founder
- spinout
- eit ecosystem
- surgery
- cardiology
- eit health
- eit supernovas
- eicfund
- headstart (eit health)
- european health catapult (eit health)
- tissue engineering
- headstart 2019 (eit health)
- regenerative medicine
- european health catapult 2020 (eit health)
- caixa impulse (eit health)
- caixa impulse 2017 (eit health)
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (93 %) | 1830 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (25 %) | (7 %) | (535 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (49 %) | (877 %) | (436 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | $0.0 | round |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
N/A | Early VC | ||
| Total Funding | 000k | ||
Related Content
Recent News about Aortyx
EditMore about Aortyx
EditDeveloper of endovascular devices intended to treat vascular diseases. The company's devices focus on tissue regeneration by mimicking the aorta biomechanical environment and provide a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta, enabling professionals to treat vascular diseases in an efficient manner.
Keywords: Healthcare Devices, Services, Supplies, Aortic Disease Treatment, Biomechanical Environment, Cell Migration, Cell Proliferation, Endovascular Device, Vascular Disease.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.